Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Trial Profile

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed; Poly ICLC
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 13 May 2019 According to a Neon Therapeutics media release, the company expects to report immune monitoring and clinical outcome data, including 12-month follow-up from this trial in first-line metastatic NSCLC patients by the end of Q3 2020.
    • 10 Apr 2019 Status changed from recruiting to active, no longer recruiting.
    • 08 Apr 2019 According to a Neon Therapeutics media release, the company expects to report immune and clinical outcome data from this trial over the course of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top